

La Renon



*New Choice for a* **PEACEFUL TOMORROW**



**POGES**

Polmacoxib 2 mg Capsules

# POGES

Polmacoxib 2 mg Capsules

## BACKGROUND:

- Osteoarthritis (OA), also known as a degenerative joint disease (DJD) is the common form of arthritis affecting millions of people worldwide.
- OA is the second most common rheumatologic problem with a prevalence of 22% to 39% in India.
- The burden and impact of OA in India are substantial and is increasing.
- Adopting suitable control and preventive treatment is needed to reduce the current and future burden of OA in India.
- Polmacoxib has the potential to be used as a pain relief drug for Osteoarthritis.

## KEY POINTS:

- Quicker onset of relief from signs and symptoms of Osteoarthritis over celecoxib.
- Superior SGA (Subject's Global Assessment) & PGA (Physicians Global Assessment) scores compared to celecoxib.
- Better gastrointestinal (GI) safety in comparison to traditional NSAIDs.
- Cardiovascular (CV) safety to potentially minimize CV side effects.
- Lowest daily dose among all known NSAIDs.

*New Choice for a* **PEACEFUL TOMORROW**



## CLINICAL EFFECTIVENESS:

### A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis

Ref: *Clinics in Orthopaedic Surgery*. 2017 Dec 1;9(4):439-57.




**No. of Participants:** 441 patients with knee or hip osteoarthritis

**Dose:** Polmacoxib 2 mg (n=146) and celecoxib 200 mg (n=145), or Placebo (n=71) once daily

**Duration:** 6 weeks

#### Result:

20.0% of subjects in the polmacoxib group and 14.9% of subjects in the celecoxib group reported their condition as “much improved” or “very much improved” by week 3 compared with 3.0% of subjects in the placebo group.



## CONCLUSION:

- Polmacoxib 2 mg is relatively well tolerated and demonstrated efficacy superior to placebo and noninferior to celecoxib after 6 weeks of treatment in patients with OA.
- The results obtained during the 18-week trial extension with polmacoxib 2 mg were consistent with those observed during the 6-week treatment period.
- It indicates that polmacoxib is considered safe for long-term use.



# POGES

Polmacoxib 2 mg Capsules

## DESCRIPTION:

POGES contains Polmacoxib available in the strength of 2 mg capsules.


## INDICATION:

POGES is indicated for the treatment of osteoarthritis.

## MECHANISM OF ACTION:

Polmacoxib has a dual mode of action:

- Binding to carbonic anhydrase I/II (CA) with high affinity which reduce the cardiovascular side effects.
- Inhibition of Cyclooxygenase-2 (COX-2) - COX-2 enzyme is responsible for the conversion of arachidonic acid into prostaglandins that are mainly involved in inflammation. Polmacoxib is a nonsteroidal anti-inflammatory drug which inhibits COX-2 to treat mild to moderate pain and help relieve the symptoms of OA.



## DOSAGE AND ADMINISTRATION:

2 mg capsule once daily or as directed by Registered Medical Practitioner.

## PRESENTATION:

Available as a strip of 10 capsules.

Reference: Clinics in Orthopaedic Surgery, 2017 Dec 1;9(4):439-57.

### La Renon Healthcare Private Limited

207-208 Iscon Elegance | Circle P | Prahlad Nagar Cross Roads  
S.G. Highway | Ahmedabad-380015 | Gujarat | India.  
Phone : 91-79-66168998 / 26936656 | Fax: +91-66168998  
E-mail : info@larenon.com | Web : www.larenon.com

Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_